Oftalmol Zh.2015;3:93-100


Антиангиогенная терапия возрастной дегенерации макулы

С. В. Шамбра, врач, С. А. Федченко, аспирант, О. В. Рябчун, аспирант, О. Н. Блавацкая, аспирант, А. Р. Король, д-р мед. наук

ГУ «Институт глазных болезней и тканевой терапии им. В. П. Филатова НАМН Украины», Одесса (Украина)

Email: laserfilatova@gmail.com

Ключевые слова: возрастная дегенерация макулы, ингибитор ФРЭС, ранибизумаб, афлиберсепт, бевацизумаб.

Ключові слова: вікова дегенерація макули, інгібітор ФРЕС, ранібізумаб, афлібірсепт, бевацізумаб.

Key words: age-related macular degeneration, vascular endothelial growth factor inhibitor, ranibizumab, aflibercept, bevacizumab.


CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration/ Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ// N Engl J Med. — 2011. — 364(20). — С.1897–1908.

Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results/ Martin DF, Maguire MG, Fine SL, et al. // Ophthalmology. — 2012. — 119(7). — С.1388–1398.

IVAN Study Investigators. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial/ Chakravarthy U, Harding SP, Rogers CA, et al. // Ophthalmology. — 2012. — 119(7). — С.1399–1411.

Kodjikian L. Overview of the GEFAL Study. Presented at: The Association for Research in Vision and Ophthalmology Annual Meeting/ Seattle, WA. — May 5–9. — 2013. 

Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration/ VIEW 1 and VIEW 2 Study Groups// Ophthalmology. — 2012. — 119(12). — С.2537–2548.

Stewart MW. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye)/ Rosenfeld PJ, Penha FM, et al. // Retina. — 2012. — 32. — С.434–457.

Hisatomi T. OCT predicts VEGF levels in human eyes/ Invest Ophthalmol VisSci. — 2013. — 54. — С.53–75.

Schmidt-Erfurth U. Intravitreal afli bercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies/ Kaiser PK, Korobelnik JF, et al. // Ophthalmology. — 2013. — 120(9). — Doi: 10.1016. — j.ophtha. — 2013.08.011.

Rofagha S. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: A multicenter cohort study (SEVEN-UP)/ Bhisitkul RB, Boyer DS, Sadda SR, Zhang K; SEVEN-UP Study Group// Ophthalmology. — 2013 May 3. — [Epub ahead of print].

Kahook MY. High-molecular-weight aggregates in repackaged bevacizumab/ Liu L, Ruzycki P, et al. // Retina. — 2010. — 30(6). — С. 887–892.

Avery R. Visual acuity response as a function of the affinity and vitreous half-life of intravitreally administered anti-VEGF agents/ Presented at: American Society of Retina Specialists 2012// Las Vegas, NV.

HARBOR Study Group. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration/ Busbee BG, Ho AC, Brown DM, et al; // Ophthalmology. — 2013. — 120(5). — С.1046–1056.

European Medicines Agency. Assessment report [aflibercept]/ Procedure No. EMEA/H/C/002392/ http://www.ema.europa.eu/docs/en_GB/ document_library// EPAR-Public_assessment_report/human/002392/ WC500135744.pdf. — Аccessed June 27, 2013.

Boyer DS. Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration/ Heier JS, Brown DM, Francom SF, Ianchulev T, Rubio RG. A// Ophthalmology. — 2009. — 116(9). — С.1731–1739.

MONT BLANC Study Group. Verteporfin plus ranibizumab for Choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results/ Larsen M, Schmidt-Erfurth U, Lanzetta P, et al; //Ophthalmology. — 2012. — 119(5). — С.992–1000.

Koh A. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy/ Lee WK, Chen LJ, et al.// Retina. — 2012. — 32(8). — С.1453–1464.

Tozer K. Combination therapy for neovascular age-related macular degeneration refractory to anti-vascular endothelial growth factor agents/ Roller AB, Chong LP, et al.// Ophthalmology. — 2013. — 120(10). — С. 2029–2034.

MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration/ Rosenfeld PJ, Brown DM, Heier JS, et al; // N Engl J Med. — 2006. — 355(14). — С.1419–1431.

ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration/ Brown DM, Kaiser PK, Michels M, et al; // N Engl J Med. — 2006. — 355(14). — С.1432–1444.

Lad EM. Treatment patterns in neovascular age-related macular degeneration between 2005–2010/ Hammill BG, Qualls LG, Wang F, Cousins SW, Curtis LH// Paper presented at: The Association for Research in Vision and Ophthalmology Annual Meeting. — Мay 5–9, 2013. — Seattle, WA. — Abstract 3819-B0129.

Holekamp NM. Real-world utilization of intravitreal antivascular endothelial growth factor agents in retinal diseases: A Claims Analysis from 2006 to 2011/ Yeh W-S, Chia YJ, Kiss S, Almony A, Kowalski J.// Paper presented at: American Society of Retina Specialists Annual Meeting. — Аugust 25–29. — 2012. — Las Vegas, NV. 

Shienbaum G. Bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen: clinical and economic impact/ Gupta OP, Fecarotta C, Patel AH, Kaiser RS, Regillo CD// Am J Ophthalmol. — 2012. — 153(3). — С.468–473.e1.

Gupta OP. A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration: clinical and economic impact/ Shienbaum G, Patel AH, Fecarotta C, Kaiser RS, Regillo CD// Ophthalmology. — 2010. — 117(11). — С.2134–2140.

Oubraham H. Inject and extend dosing versus dosing as needed: a comparative retrospective study of ranibizumab in exudative age-related macular degeneration/ Cohen SY, Samimi S, et al.// Retina. — 2011. — 31(1). — С.26–30.

Toalster N. A 12-month prospective trial of inject and extend regimen for ranibizumab treatment of age-related macular degeneration/ Russell M, Ng P// Retina. — 2013. — 33(7). — С.1351–1358.

Hassan TS. Patient perceptions of the treatment regimen and expected outcomes of intravitreal anti-VEGF injections for wet age-related macular degeneration/ Luo CK, Willimas GA. Paper presented at: American Society of Retina Specialists Annual Meeting// August 25–29. — 2012. — Las Vegas, NV.

Eghøj MS. Tachyphylaxis during treatment of exudative age-related macular degeneration with Ranibizumab/ Sørensen TL// Br J Ophthalmol. — 2012. — 96(1). — С.21–23.

Gasperini JL. Bevacizumab and Ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation/ Fawzi AA, Khondkaryan A, et al.// Br J Ophthalmol. — 2012. — 96(1). — С.14–20.

Cho H. Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab/ Shah CP, Weber M, Heier JS// Br J Ophthalmol. — 2013. — 97(8). — С.1032–1035.

Lyall DA. Post-intravitreal anti-VEGF endophthalmitis in the United Kingdom: incidence, features, risk factors, and outcomes/ Tey A, Foot B, et al. // Eye (Lond). — 2012. — 26(12). — С.1517–1526.

McCannel CA. Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies/Retina. — 2011. — 31(4). — С.654–661.

Doshi RR. Reducing oral flora contamination of Intravitreal injections with face mask or silence/ Leng T, Fung AE// Retina. — 2012. — 32(3). — С.473–476.

Wen JC. Bacterial dispersal associated with speech in the setting of intravitreous injections/ McCannel CA, Mochon AB, Garner OB// Arch Ophthalmol. — 2011. — 129(12). — С.1551–1554.

Lavole D. Victims in meningitis outbreak hope for criminal charges against compounding pharmacy/ NBC News Digital// November 25, 2013.http://www.nbcnews.com/health/victims-meningitis-outbreak-hope-criminal-.... — Accessed December 2, 2013.

Король А. Р. Сравнительный анализ эффективности лечения пациентов с экссудативной формой возрастной дегенерации макулы ингибиторами ангиогенеза в зависимости от степени тяжести / А. Р. Король // Офтальмол. журн. — 2013 — № 1. — С. 30–37.

Король А. Р. Гемодинамика в сосудистой оболочки у пациентов с экссудативной формой ВДМ в ходе лечения ингибиторами ангиогенеза и значение медикаментозной коррекции / А. Р. Король, Н. И. Храменко, О. С. Задорожный и др. // Офтальмол. журн. — 2013 — № 2. — С. 51–55.